Tags

Type your tag names separated by a space and hit enter

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
BMC Cancer. 2017 05 22; 17(1):354.BC

Abstract

BACKGROUND

The Ki67 labeling index (LI) is regarded as a significant prognostic marker in ER-positive/HER2-negative breast cancer patients. The expression of PgR has recently been identified as another prognostic marker. In the present study, we investigated the prognostic utilities and most suitable cut-off values for Ki67 and PgR, and evaluated the relationship between Ki67 LI and PgR expression in ER-positive/HER2-negative breast cancer.

PATIENTS AND METHODS

In the present study, 177 consecutive Japanese women with ER-positive/HER2-negative invasive carcinoma of no special type who were treated between 2000 and 2001 were enrolled. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were analyzed according to Ki67 LI and PgR expression, and significant cut-off values for selecting patients with a poor prognosis were evaluated.

RESULTS

The cut-off values for Ki67 LI as a prognostic marker plotted against P values showed bimodal peaks at 10% and 30%. Among the cut-off points examined for the PgR status, 20% PgR positivity was the most significant for predicting survival differences (RFS: P = 0.0003; CSS: P < 0.0001). A multivariate analysis showed that PgR (≥20%) was an independent prognostic marker (RFS: P = 0.0092; CSS: P = 0.00014). Furthermore, in the intermediate risk group with Ki67 LI of 10-30%, the low PgR <20% group had a markedly poorer prognosis for RFS and CSS (RFS: P < 0.0001; CSS: P < 0.0001).

CONCLUSIONS

The expression of PgR is a potent prognostic indicator for evaluating the long-term prognosis of ER-positive/HER2-negative breast cancer, and the most suitable cut-off value was found to be 20%. Furthermore, the PgR status is a powerful method for selecting patients with a poor prognosis among ER-positive/HER2-negative patients at intermediate risk, as assessed using Ki67 LI.

Authors+Show Affiliations

Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan. Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Gunma, Japan.Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan.Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan.Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan.Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan.Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Gunma, Japan.Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Gunma, Japan.Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, Gunma, Japan.Department of Pathology, Saitama Cancer Center, 780 Komuro, Ina-machi, Kitaadachi-gun, Saitama, 362-0806, Japan. mkurosumi@cancer-c.pref.saitama.jp.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

28532429

Citation

Kurozumi, Sasagu, et al. "Power of PgR Expression as a Prognostic Factor for ER-positive/HER2-negative Breast Cancer Patients at Intermediate Risk Classified By the Ki67 Labeling Index." BMC Cancer, vol. 17, no. 1, 2017, p. 354.
Kurozumi S, Matsumoto H, Hayashi Y, et al. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index. BMC Cancer. 2017;17(1):354.
Kurozumi, S., Matsumoto, H., Hayashi, Y., Tozuka, K., Inoue, K., Horiguchi, J., Takeyoshi, I., Oyama, T., & Kurosumi, M. (2017). Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index. BMC Cancer, 17(1), 354. https://doi.org/10.1186/s12885-017-3331-4
Kurozumi S, et al. Power of PgR Expression as a Prognostic Factor for ER-positive/HER2-negative Breast Cancer Patients at Intermediate Risk Classified By the Ki67 Labeling Index. BMC Cancer. 2017 05 22;17(1):354. PubMed PMID: 28532429.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index. AU - Kurozumi,Sasagu, AU - Matsumoto,Hiroshi, AU - Hayashi,Yuji, AU - Tozuka,Katsunori, AU - Inoue,Kenichi, AU - Horiguchi,Jun, AU - Takeyoshi,Izumi, AU - Oyama,Tetsunari, AU - Kurosumi,Masafumi, Y1 - 2017/05/22/ PY - 2017/01/09/received PY - 2017/05/08/accepted PY - 2017/5/24/entrez PY - 2017/5/24/pubmed PY - 2018/3/13/medline KW - ER-positive and HER2-negative breast cancer KW - Ki67 labeling index KW - Progesterone receptor KW - Prognosis SP - 354 EP - 354 JF - BMC cancer JO - BMC Cancer VL - 17 IS - 1 N2 - BACKGROUND: The Ki67 labeling index (LI) is regarded as a significant prognostic marker in ER-positive/HER2-negative breast cancer patients. The expression of PgR has recently been identified as another prognostic marker. In the present study, we investigated the prognostic utilities and most suitable cut-off values for Ki67 and PgR, and evaluated the relationship between Ki67 LI and PgR expression in ER-positive/HER2-negative breast cancer. PATIENTS AND METHODS: In the present study, 177 consecutive Japanese women with ER-positive/HER2-negative invasive carcinoma of no special type who were treated between 2000 and 2001 were enrolled. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were analyzed according to Ki67 LI and PgR expression, and significant cut-off values for selecting patients with a poor prognosis were evaluated. RESULTS: The cut-off values for Ki67 LI as a prognostic marker plotted against P values showed bimodal peaks at 10% and 30%. Among the cut-off points examined for the PgR status, 20% PgR positivity was the most significant for predicting survival differences (RFS: P = 0.0003; CSS: P < 0.0001). A multivariate analysis showed that PgR (≥20%) was an independent prognostic marker (RFS: P = 0.0092; CSS: P = 0.00014). Furthermore, in the intermediate risk group with Ki67 LI of 10-30%, the low PgR <20% group had a markedly poorer prognosis for RFS and CSS (RFS: P < 0.0001; CSS: P < 0.0001). CONCLUSIONS: The expression of PgR is a potent prognostic indicator for evaluating the long-term prognosis of ER-positive/HER2-negative breast cancer, and the most suitable cut-off value was found to be 20%. Furthermore, the PgR status is a powerful method for selecting patients with a poor prognosis among ER-positive/HER2-negative patients at intermediate risk, as assessed using Ki67 LI. SN - 1471-2407 UR - https://www.unboundmedicine.com/medline/citation/28532429/Power_of_PgR_expression_as_a_prognostic_factor_for_ER_positive/HER2_negative_breast_cancer_patients_at_intermediate_risk_classified_by_the_Ki67_labeling_index_ DB - PRIME DP - Unbound Medicine ER -